|
Release Date
June 8, 2010
|
Expiration Date
June 8, 2011 |
|
|
| Faculty |
Sanjiv Agarwala, MD
St. Luke’s Cancer Center
Bethlehem, Pennsylvania, United States |
Dean Bajorin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
Lisa Carey, MD
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
Mary Cianfrocca, DO
Northwestern University
Chicago, Illinois, United States
|
|
Gini Fleming, MD
University of Chicago
Chicago, Illinois, United States
|
Aristoteles Giagounidis, MD, PhD
St. Johannes Hospital
Duisburg, Germany
|
William J. Gradishar, MD
Northwestern University
Chicago, Illinois, United States
|
Hagop Kantarjian, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas, United States
|
|
Vernon Sondak, MD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
|
Julie Vose, MD
University of Nebraska Medical Center
Omaha, Nebraska, United States
|
|
|
Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other healthcare providers involved and/or interested in the care of patients with cancer.
|
Overview
These interviews are regarding recently released data from the 2010 Oncology Annual Meeting in Chicago, focusing on various aspects of the management of patients with cancer. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Discuss clinically relevant advancements in the management of breast cancer in both the early and metastatic settings
- Describe recent advances in the treatment of melanoma, and evaluate clinical trial data supporting the use of targeted agents in this setting
- Explain novel treatment strategies into the management of patients with genitourinary malignancies
- Evaluate contemporary therapeutic approaches for the management of patients with gynecologic malignancies, and review the latest advances in improving survival rates and quality of life in this patient population
- Recommend state-of-the-art treatment strategies for patients with hematologic malignancies
|
Sponsorship Statement
This activity is jointly sponsored by Indiana University School of Medicine and prIME Oncology. |
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Indiana University School of Medicine (IUSM) and prIME Oncology. Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. |
Credit Designation Statement
Indiana University School of Medicine designates this educational activity for a maximum of .5 AMA PRA Category 1 Credits™ per interview for a total maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in Indiana University School of Medicine's database. However, upon request, your CME credit certificate will be e-mailed to you.
Links to the post-tests are available on the activity selection page and video player pages.
|
Support Statement
This activity is supported by educational grants from Bristol-Myers Squibb; Novartis Oncology; and sanofi-aventis. |
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, educational activities sponsored by IUSM must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Dr Agarwala has disclosed that he has received speakers’ fees from Novartis Pharmaceuticals Corporation; Schering-Plough Corporation; and sanofi-aventis. None of these relationships will impact his ability to present an unbiased discussion.
Dr Bajorin has disclosed that he has received research funding from Amgen Inc.; Genentech; and Pfizer Inc. He has also received consulting fees from Bristol-Myers Squibb Company and Eli Lilly and Company, and he has received speakers’ fees from Eli Lilly and Company and Novartis Pharmaceuticals Corporation. None of these relationships will impact his ability to present an unbiased discussion.
Dr Carey has disclosed that she has no real or apparent conflicts of interest to report and no relevant financial relationships with any commercial interests.
Dr Cianfrocca has disclosed that she has received research funding from GlaxoSmithKline and speakers’ fees from Genentech. None of these relationships will impact her ability to present an unbiased discussion.
Dr Fleming has disclosed that she has received support for an investigator-initiated trial from Wyeth Pharmaceuticals, Inc. This relationship will not impact her ability to present an unbiased discussion.
Dr Giagounidis has disclosed that he has received consulting fees and honoraria from Celgene Corporation. This relationship will not impact his ability to present an unbiased discussion.
Dr Gradishar has disclosed that he has no real or apparent conflicts of interest to report and no relevant financial relationships with any commercial interests.
Dr Kantarjian has disclosed that he has received research grants from Bristol-Myers Squibb Company; Genzyme Corporation; Novartis Pharmaceuticals Corporation; and Wyeth Pharmaceuticals, Inc. None of these relationships will impact his ability to present an unbiased discussion.
Dr Lokey has disclosed that he has no real or apparent conflicts of interest to report and no relevant financial relationships with any commercial interests.
Dr Sondak has disclosed that he has received consulting fees from Abbott Laboratories; Bayer HealthCare Corporation; Bristol-Myers Squibb Company/Medarex Inc; Eli Lilly and Company; GlaxoSmithKline; MERCK & CO., Inc. (Schering); Onyx Pharmaceuticals; Pfizer Inc; and Synta Pharmaceuticals Corporation. He has also received speakers’ fees from Merck/Schering. None of these relationships will impact his ability to present an unbiased discussion.
Dr Vose has disclosed that she has received research grants from Allos Therapeutics, Inc.; Astellas Pharmaceuticals; Bristol-Myers Squibb Company; Celgene Corporation; Genentech; GlaxoSmithKline; Millennium, The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Pharmacyclics; and Rigel Pharmaceuticals, Inc. None of these relationships will impact her ability to present an unbiased discussion.
The employees of prIME Oncology have disclosed:
- Michael Checkoway (project management) – no real or apparent conflicts of interest
- Amy White, RN (clinical) – no real or apparent conflicts of interest
- Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Indiana University School of Medicine, prIME Oncology, and the supporters of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of IUSM or prIME Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
|
